The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Global Autoinjectors Market, 2016 - 2026

  • Lowest Price Guaranteed From USD 2,349

  • Published
    May 2016

  • Pages
    380

  • View Count
    3154

Example Insights

An updated edition is available at the following link 

View 3rd edition

  1. During our research, we identified over 80 autoinjectors being developed or commercially available by more than 20 companies. Over 50 drugs as combination products have been commercialized so far; several companies such as Amgen, GSK, Sanofi and Palatin Technologies are testing their late stage pipeline drugs with autoinjectors.
  2. Most of the autoinjectors being developed are disposable devices, contributing a share of 62%; reusable / rechargeable / electronic autoinjectors have also emerged providing options for multiple dosing of the drugs.
  3. Some of the established pharmaceutical stakeholders working in this domain include BD, Bespak, Changzhou Delfu, Elcam Medical, DALI Medical Devices, Meridian Medical Technologies, Owen Mumford, SHL Group, Union Medico, West Pharmaceutical Services and Ypsomed. Several new / small companies have entered with their innovative technologies and devices. Examples of such innovators include Amedra Pharmaceuticals, ChemProtect SK, Future Injection Technologies, Haselmeier AG, Kaleo Pharma, Nuance, Nemera, Oval Medical Technologies, Unilife and Xeris Pharmaceuticals.
  4. Developers are focusing on introducing a variety of advanced features to make these devices more user-friendly. Specific examples include push-on-skin release, one-handed operation, twist & mix mechanism, automatic reconstitution / priming, anti-roll, compact and sleek designs. Smart electronic autoinjectors are being developed featuring bluetooth connectivity, LCD screen and special software to connect the device or part of the device with computer systems to maintain injection records. Some of the devices, such as Safelia™ autoinjector (Nemera) and Syrina™ AR (Bespak), are also capable of delivering drugs with high volume and high viscosity.
  5. A variety of novel technologies have emerged for the development of autoinjectors. Examples of such technologies include Breeze™ technology (Nuance Designs), Depot Control technology (Union Medico), VapourSoft™ technology (Bespak), Rotaject™ Pressure Release technology, NIT™ technology, Negasai™ spring technology and Pushclick™ technology (SHL Group).
  6. Although autoinjectors have been in the market for over two decades, the market is still evolving. There is widespread optimism that such devices hold significant opportunity for the pharmaceutical companies; the rapidly evolving pipeline of biologics and biosimilars will act as a major driver.
  7. We anticipate the global autoinjectors market to grow at an annualized growth rate of over 8% in the next ten years. Launch in emerging regions such as India and China, availability of such devices for other chronic (in addition to multiple sclerosis and rheumatoid arthritis) and emergency indications (in addition to anaphylaxis), introduction of life cycle management projects for drugs nearing patent expiry are some of the opportunity areas wherein the companies are likely to focus on.

Overview

With the rising trend towards self-injection devices and rapidly growing pipeline of the biologics / biosimilars, autoinjectors have recently emerged as an important class of medical devices. Compared to conventional delivery systems, these devices automate the process of delivering drugs through subcutaneous or intramuscular routes. Autoinjectors are primarily spring-driven systems and use fillable / prefilled syringes or cartridges as primary containers. Due to their numerous benefits including easy self-administration, improved patient compliance, reduced anxiety and dosage errors, these devices have gained a lot of popularity from both pharmaceutical companies and end-users. The growing concern about the hazards associated with the needlestick injuries and other safety concerns has given an additional push to the market.

The origin of autoinjectors dates back to 1960s when a self-administered device was developed with a primary motive for use in military purposes to inject the antidote for nerve agents in biological weapons. Subsequently, EpiPen® by Pfizer / Mylan became the first disposable autoinjector to hit the US commercial market and received marketing approval in 1980s for the treatment of anaphylaxis. Following this, several autoinjectors were approved for various therapeutic indications. Anaphylaxis, so far, has continued to dominate the overall market. Autoinjectors for other chronic / emergency indications such as multiple sclerosis, rheumatoid arthritis, migraine, psoriasis and diabetes have also witnessed rising adoption.

It is well-known that pharmaceutical companies have frequently collaborated with device manufacturing companies to develop innovative drug delivery systems for their respective marketed / pipeline drugs. Several drugs have been approved in combination with autoinjectors in the past few years. Examples of such drugs include SIMPONI®, AVONEX®, PLEGRIDY®, EVZIO®, Repatha, ORENCIA®, Trulicity®, ACTEMRA®, Otrexup™, Cosentyx® and COPAXONE®. In addition, these devices act as a life cycle management tool for drugs for which the patent has already expired or is close to expiry.

The increased interest has driven medical device manufacturers to introduce next generation of autoinjectors with advanced features and innovative designs making drug administration relatively more safe and convenient. Reformulation of first generation biologics, growing prevalence of chronic diseases, urgent treatment required in emergency conditions, needle safety regulations and technological advancements in this area are some of the factors that will drive this market in the near future.

 

Scope of the Report

The ‘Global Autoinjectors Market, 2016-2026' report provides a comprehensive analysis of the current state of autoinjectors market and the likely future evolution of these devices over the next decade. Starting with an overview of self-administration devices, the report elaborates on the origin / history of autoinjectors, their components and advantages offered by different categories of autoinjectors. It also covers information on needlestick injuries and looks at the safety laws and legislations across major regional markets for prefilled syringes that are incorporated as primary drug containers in autoinjectors.

One of the key objectives of the study is to enumerate various autoinjectors available in the market, combination products currently available / being developed and the corresponding market potential across different therapeutic areas. Amongst other elements, the report elaborates on the following key areas:

  • The current state of the market with respect to key players, routes of administration, primary drug containers, usability, indications and drugs being targeted.
  • 2 X 2 matrices depicting the product competitiveness and supplier power across the growing landscape of disposable and reusable autoinjectors.
  • Detailed case studies on the drugs that have been potential targets for autoinjectors. 
  • List of likely candidates for delivery via autoinjectors based upon their route of administration, targeted indication and dosage regime.
  • Detailed company profiles of the key autoinjector manufacturers as well as emerging players that are trying to build a foothold in this industry.
  • The future growth opportunities likely to drive the market in the short term and long term.

The study also focuses on analyzing the existing market size and potential future growth of these drug delivery devices across different therapeutic classes, routes of administration and extent of usability. The report provides sales forecast for the overall autoinjectors market for the period 2016 - 2026. It takes into account the price variation that is likely to occur as a result of mass adoption and increased competition. For the purposes of the study, we interviewed important stakeholders to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. 2015 is the base year; actual figures have been sourced and analyzed from publicly available information. Unless otherwise specified, all figures are presented in USD.

Contents

Chapter 2  provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of autoinjectors market.

Chapter 3  provides a general overview of the various self-injection devices and autoinjectors. It covers the historical evolution of autoinjectors, their components, categories and associated manufacturing/packaging processes. In addition, it elaborates on the benefits of autoinjectors that have led to a growing adoption over the last several years. The chapter also highlights the issue of needlestick injuries and various preventive laws worldwide that have put the focus on introducing safety features in these devices.

Chapter 4  includes an introduction on the types of primary drug containers that are utilized in autoinjectors. Broadly, it covers an overview on the current trends coming up in the market of prefilled syringes and cartridges. It also lists the key manufacturers of these primary drug containers.

Chapter 5  provides a comprehensive analysis of the current market of autoinjectors. It lists over 80 autoinjector devices (including variants) that can be used to carry out self-administration for a variety of application areas. For these devices, we have identified the type and volume of the primary drug container used, usability, route of administration, needle size and other technical parameters. The chapter also includes list of combination products that have been approved or are under development with respect to indications being targeted. For both disposable and reusable autoinjectors, we have presented 2 X 2 matrices to compare the relevant product competitiveness and supplier power.

Chapter 6  presents a list of therapeutic drugs that are currently available in autoinjectors. It also provides case studies on the most common drugs / indications targeted. In addition, we have put together a list of potential molecules, based upon the route of administration, indication targeted and dosage regime, which are likely to form the target drugs for delivery via autoinjectors in the future.

Chapter 7  provides detailed profiles of key autoinjector manufacturers highlighting information on the company overview, financial performance, technology overview, product portfolio, collaborations and recent developments. Key players covered in this section include  (in alphabetical order)  Bespak, DALI Medical Devices, Elcam Medical, Meridian Medical Technologies, Owen Mumford, SHL Group, Union Medico and Ypsomed Delivery Systems.

Chapter 8  discusses profiles of new entrants in the autoinjectors industry. These profiles cover information on their company overview, technology overview, product portfolio and recent developments. Emerging players covered in this section include  (in alphabetical order)  Amedra Pharmaceuticals, Kaleo Pharma, Nuance Design, Oval Medical Technologies, Xeris Pharmaceuticals and Zion Clinical Pharmacy.

Chapter 9  provides a detailed description of the likely evolution of autoinjectors market. We have adopted a ‘top down’ approach, backed by robust data and credible inputs from primary research, to identify the likely size of the market, both in terms of value (USD billion) and volume (number of devices).

Chapter 10  highlights the key future growth opportunities likely to increase market share of manufacturers active in this area. These include life cycle management, growing pipeline of biologics and biosimilars, emerging target indications, launch of autoinjectors in other regions and introduction of specific advanced and user friendly features in these devices.

Chapter 11  is a collection of interview transcripts. For the purpose of our study, we contacted number of stakeholders in order to ascertain the key strategic initiatives and future roadmap of the industry. These include Douglas Marenzi (Managing Director, PHC) and Tsachi Shaked (Senior Marketing and BD Director, Injectable Drug Delivery Devices, Elcam Medical). Other participants requested anonymity.

Chapter 12  summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 13  is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 14  is an appendix, which provides a list of companies and organizations mentioned in this report.

Table of Contents

1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. Executive Summary
 
3. Introduction
3.1. Chapter Overview
3.2. Drug Delivery Devices
3.3. Conventional Parenteral Delivery Using a Needle and Syringe
3.4. Self-Administration: An Emerging Trend
3.4.1. Rising Burden of Chronic Diseases
3.4.2. Need for Immediate Treatment in Emergency Situations
3.4.3. Expansion of Injectable Biologic Products
3.5. Types of Self- Injection Devices
3.5.1. Prefilled Syringes
3.5.2. Pen-Injectors
3.5.3. Needle-Free Injectors
3.5.4. Autoinjectors
3.5.5. Large Volume Wearable Injectors
3.6. Self-Injection Devices Market
3.7. Needlestick Injuries
3.7.1. Incidence And Cost Burden
3.7.2. Prevention
3.7.3. Government Legislation for the Prevention of Needlestick Injuries
3.7.4. Safety Options in Self-Injectors
3.8. Autoinjectors: An Important Class of Self-Injection Devices
3.8.1. Components of Autoinjectors
3.8.2. Classification of Autoinjectors
3.8.2.1. On the Basis of Mechanism
3.8.2.2. On the Basis of Usability
3.8.2.3. On the Basis of Dose Delivered
3.8.3. Manufacturing/Packaging
3.8.4. Benefits of Autoinjectors
3.9. Regulatory Considerations
3.10. Drug Device Combination Products
 
4. Primary Drug Containers in Autoinjectors
4.1. Chapter Overview
4.2. Primary Drug Container
4.2.1. Vials
4.2.2. Cartridges
4.2.2.1. Components of Cartridges
4.2.2.2. Glass: Historical Material of Choice
4.2.2.3. Types of Cartridges
4.2.2.3.1. Single Chamber Cartridge
4.2.2.3.2. Dual Chamber Cartridge
4.2.2.4. Applications of Cartridges
4.2.2.5. Drawbacks of Cartridges
4.2.2.6. Companies Developing Cartridges
4.2.3. Prefilled Syringes
4.2.3.1. Components of Prefilled Syringes
4.2.3.2. Classification of Prefilled Syringes
4.2.3.2.1. Based on Barrel Material
4.2.3.2.2. Based on Number of Chambers
4.2.3.2.3. Based on Type of Needle
4.2.3.3. Prefilled Syringes: Key Benefits
4.2.3.3.1. Benefits over Traditional Injectable Devices
4.2.3.3.2. Benefits for Healthcare Professionals and End Users
4.2.3.3.3. Benefits for Manufacturers
4.2.3.4. Advantages of Plastic Prefilled Syringes
4.2.3.5. Prefilled Syringe Systems Available in the Market
4.2.3.5.1. Glass Prefilled Syringes
4.2.3.5.2. Plastic Prefilled Syringes
 
5. Autoinjectors: Current Market Landscape
5.1. Chapter Overview
5.2. Autoinjectors: Overall Market Overview
5.2.1. Autoinjectors: Distribution by Players
5.2.2. Autoinjectors: Distribution by Type of Primary Drug Container
5.2.3. Autoinjectors: Distribution by Usability
5.2.4. Autoinjectors: Distribution by Type of Dosage
5.2.5. Autoinjectors: Distribution by Route of Administration
5.3. Approved Combination Products: Overall Market Overview
5.3.1. Approved Combination Products: Distribution by Players
5.3.2. Approved Combination Products: Distribution by Target Indication
5.3.3. Approved Combination Products: Distribution by Type of Primary Drug Container
5.3.4. Approved Combination Products: Distribution by Usability
5.3.5. Approved Combination Products: Distribution by Route of Administration
5.3.6. Approved Combination Products: Distribution by Target Drug
5.4. Pipeline Combination Products: Overall Market Overview
5.5. Product Competitiveness Analysis
5.5.1. Product Competitiveness Analysis for Disposable Autoinjectors
5.5.2. Product Competitiveness Analysis for Semi-Disposable/ Reusable Autoinjectors
 
6. Case Studies
6.1. Chapter Overview
6.2. Drugs Available / Being Evaluated With Autoinjectors
6.3. Case Study I: Adrenaline/Epinephrine
6.3.1. Overview
6.3.2. Mechanism of Action
6.3.3. Anaphylaxis: Overview and Epidemiology
6.3.4. History of Development
6.3.5. Adrenaline/ Epinephrine Autoinjectors
6.3.5.1. Marketed Adrenaline/ Epinephrine Autoinjectors
6.3.5.1.1. Adrenaclick®
6.3.5.1.2. Allerject / Auvi-Q® (Formerly called e-cue™)
6.3.5.1.3. Anapen®
6.3.5.1.4. Emerade®
6.3.5.1.5. EpiPen®
6.3.5.1.6. Jext®
6.3.5.2. Adrenaline/ Epinephrine Autoinjectors Under Development
6.3.5.2.1. Oval Autoinjector
6.3.5.2.2. Abiliject
6.3.6. Other Dosage Forms
6.3.7. Historical Sales
 
6.4. Case Study II: Interferon beta-1a/ Interferon beta-1b (Multiple Sclerosis)
6.4.1. Overview
6.4.1.1. Interferon beta-1a
6.4.1.2. Interferon beta-1b
6.4.2. Mechanism of Action
6.4.3. Multiple Sclerosis: Overview and Epidemiology
6.4.4. History of Development
6.4.5. Interferon-beta Autoinjectors
6.4.5.1. Interferon beta-1a Autoinjectors
6.4.5.1.1. Avonex Pen®
6.4.5.1.2. PLEGRIDY Pen
6.4.5.1.3. Rebif ® Rebidose®
6.4.5.1.4. RebiSmart™
6.4.5.1.5. Rebiject II®
6.4.5.2. Interferon beta-1b Autoinjectors
6.4.5.2.1. BETACONNECT™
6.4.5.2.2. BETAJECT® Comfort/ Betacomfort®
6.4.5.2.3. Betaject® Lite
6.4.5.2.4. ExtaviJect® 30G/ ExtaviPro® 30G
6.4.6. Other Dosage Forms
6.4.7. Historical Sales
6.4.7.1. Interferon beta-1a
6.4.7.2. Interferon beta-1b
 
6.5. Likely Targets for Autoinjectors
6.5.1. Marketed Molecules
6.5.1.1. Marketed Molecules: Most Likely Candidates for Autoinjectors
6.5.1.2. Marketed  Molecules: Likely Candidates for Autoinjectors
6.5.1.3. Marketed  Molecules: Less Likely Candidates for Autoinjectors
6.5.2. Pipeline Molecules
6.5.2.1. Pipeline Molecules: Most Likely Candidates for Autoinjectors
6.5.2.2. Pipeline Molecules: Likely Candidates for Autoinjectors
6.5.2.3. Pipeline Molecules: Less Likely Candidates for Autoinjectors
 
7. Key Players
7.1. Chapter Overview
7.2. Bespak
7.2.1. Company Overview
7.2.2. Financial Performance
7.2.3. Technology Overview
7.2.4. Product Portfolio
7.2.4.1. Autoinjectors
7.2.4.1.1. Syrina™
7.2.4.1.2. ASI™ Autoinjector
7.2.4.1.3. OTS™ Autoinjector
7.2.5. Recent Developments
7.2.5.1. Collaborations
7.2.5.1.1. Aesica Pharmaceuticals
7.2.5.1.2. Undisclosed Global Generic Company
7.2.5.1.3. Undisclosed Global Pharmaceutical Company
7.2.5.1.4. Martindale Products and Specials
7.2.6. Future Outlook
 
7.3. Changzhou Delfu Technology
7.3.1. Company Overview
7.3.2. Financial Performance
7.3.3. Product Portfolio
7.3.3.1. Autoinjectors: Overview and Specifications
7.3.3.1.1. Components of Delfu Autoinjectors
7.3.3.1.2. Applications of Delfu Autoinjectors
7.3.3.1.3. Features of Delfu Autoinjectors
7.3.3.1.4. Advantages of Delfu Autoinjectors
7.3.3.1.5. Specifications of Delfu Autoinjectors
7.3.3.2. Autoinjectors: Product Details
7.3.3.2.1. YZ-II 3mLCartridge Digital Dose Setting GF Autoinjector
7.3.3.2.2. DZ-IA 3 mL Cartridge Needle Hidden Vaccination Autoinjector
7.3.3.2.3. DZ-IA Auto Injector Pen
7.3.3.2.4. YZ-III Standard 3 mL Cartridge Reusable Electronic Auto Injector Pen
7.3.3.2.5.YZ-III 0.001mL Dose Increments Fully Automated Reusable Injectors
7.3.3.2.6.YZ-III 0.001 mL Dose Accuracy Auto Injector Pen
7.3.3.2.7.YZ-II 3mL* 1u Auto inject Pen
7.3.3.2.8.YZ-V 3 mL Cartridge Replaceable Variable-dose Classic Auto Injector Pen
7.3.3.2.9.YZ-III Automatic Reusable Insulin Injection Pen
 
7.4. DALI Medical Devices
7.4.1. Company Overview
7.4.2. Product Portfolio
7.4.2.1. Autoinjectors
7.4.2.1.1. SAN-L
7.4.2.1.2. SAN-P
7.4.2.1.3. SAN-DV
7.4.2.1.4. SAN-DV Pro
 
7.5. Elcam Medical (E3D Elcam Drug Delivery Devices)
7.5.1. Company Overview
7.5.2. Product Portfolio
7.5.3. Autoinjectors
7.5.3.1. Flexi-Q Disposable Autoinjectors
7.5.3.1.1. Flexi-Q PFS
7.5.3.1.2. Flexi-Q HV
7.5.3.1.3. Flexi -Q DV
7.5.3.2. Flexi-Q Reusable Autoinjectors
7.5.3.2.1. Flexi-Q mMU
7.5.3.2.2. Flexi-Q eMU
7.5.3.3. Comparison of Elcam Medical Autoinjectors
7.5.4. Recent Developments
7.5.4.1. Collaborations
7.5.5. Future Outlook
 
7.6. Meridian Medical Technologies
7.6.1. Company Overview
7.6.2. Product Portfolio
7.6.2.1. Antidote Treatment Nerve Agent, Autoinjector (ATNAA): Atropine and Pralidoxime Chloride Injection
7.6.2.2. AtroPen® Autoinjector: Atropine Injection
7.6.2.3. Diazepam Autoinjector C-IV: Diazepam Injection
7.6.2.4. DuoDote® Autoinjector: Atropine and Pralidoxime Chloride Injection
7.6.2.5. Morphine Autoinjector C-II: Morphine Sulfate Injection
7.6.2.6. Pralidoxime Chloride Autoinjector: Pralidoxime Chloride Injection
7.6.2.7. Comparison of Meridian Medical Technologies Autoinjectors
7.6.2.8. EpiPen®
7.6.2.9. ALSUMA®  / Sumatriptan Autoinjector
7.6.2.10. Vanquix™ Autoinjector
7.6.2.11. Investigational Midazolam Autoinjector
7.6.3. Technology
7.6.4. Future Outlook
 
7.7. Owen Mumford
7.7.1. Company Overview
7.7.2. Product Portfolio
7.7.2.1. Autoinjectors
7.7.2.1.1. Autoject® Micro
7.7.2.1.2. Autoject® 2
7.7.2.1.3. Autoject® Mini
7.7.2.1.4. Autoject Uni
7.7.2.1.5. Autoject Multi
7.7.2.1.6. Autoject® Flex
7.7.3. Future Outlook
 
7.8. Scandinavian Health Limited (SHL) Group
7.8.1. Company Overview
7.8.2. Product Portfolio
7.8.2.1. Two-Step Disposable Autoinjectors
7.8.2.1.1. Amber® (Pushclick™ Technology)
7.8.2.1.2. Molly®
7.8.2.1.3. Molly® RNS
7.8.2.1.4. Molly® 2.25
7.8.2.1.5. Molly®  C
7.8.2.1.6. NAISA® (Negasai™ Spring Technology)
7.8.2.1.7. Comparison of SHL Two-Step Autoinjectors
7.8.2.2. Three-Step Disposable Autoinjectors
7.8.2.2.1. DAI®
7.8.2.2.2. DAI® -RNS
7.8.2.2.3. DAI® -R
7.8.2.2.4. SDI-MIX® +NIT™ (Needle Isolation Technology and Twist and Mix Mechanism)
7.8.2.2.5. VSDI-MIX™
7.8.2.2.6. PSDI®
7.8.2.2.7. Comparison of SHL Three-Step Autoinjectors
7.8.2.3. PPI® Injector (Rotaject™ Pressure Release Technology)
7.8.3. Recent Developments
7.8.4. Collaborations
7.8.5. Future Outlook
 
7.9. Union Medico
7.9.1. Company Overview
7.9.2. Technology
7.9.3. Product Portfolio
7.9.3.1. 45˚ Autoinjector
7.9.3.1.1. 45˚ /S Autoinjector
7.9.3.1.2. 45˚ /M Autoinjector
7.9.3.1.3. 45˚ /R Autoinjector
7.9.3.1.4. Comparison of 45˚ Autoinjectors
7.9.3.2. 90˚ Autoinjector
7.9.3.2.1. 90˚ /S Autoinjector
7.9.3.2.2. 90˚ / M Autoinjector
7.9.3.2.3. 90˚ / XL Autoinjector
7.9.3.2.4. SuperGrip™ Autoinjector
7.9.3.2.5. Exclusive™ Autoinjector
7.9.3.2.6. Comparison of 90˚ Autoinjectors
7.9.4. Future Outlook
 
7.10. Ypsomed
7.10.1. Company Overview
7.10.2. Financial Performance
7.10.3. Product Portfolio
7.10.3.1. Pen-Injectors
7.10.3.2. Autoinjectors
7.10.3.2.1.YpsoMate® and YpsoMate® 2.25
7.10.3.2.2.VarioJect™
7.10.3.2.3.YpsoMate® Smart
7.10.3.3. Comparison of Ypsomed Autoinjectors
7.10.4. Recent Developments
7.10.4.1. Investment in Solothurn Facility
7.10.4.2. Development of a New Generation of Injection and Infusion Systems
7.10.4.3. Formative Study of Ypsomed Disposable Autoinjector: Results
7.10.4.4. Plan to Increase Production Capacity
7.10.4.5. Geographical Expansion
7.10.5. Collaborations
7.10.5.1. Thinfilm Electronics
7.10.5.2. Tonghua Dongbao Pharmaceutical
7.10.5.3. Terumo Corporation
7.10.5.4. Hanmi Pharmaceutical
7.10.6. Future Outlook
 
8. Emerging Players
8.1. Chapter Overview
8.2. Amedra Pharmaceuticals (Impax Laboratories)
8.2.1. Company Overview
8.2.2. Product Portfolio
8.2.2.1. Adernaclick® Autoinjector
 
8.3. Kaleo Pharma
8.3.1. Company Overview
8.3.2. Product Portfolio
8.3.2.1. Auvi-Q® /Allerject
8.3.2.2. EVZIO® Autoinjector
8.3.3. Recent Developments
 
8.4. Nuance Designs
8.4.1. Company Overview
8.4.2. Technology Overview
8.4.3. Product Portfolio
8.4.3.1. Fusion™ Autoinjector
8.4.3.2. Quantum™ Autoinjector
 
8.5. Oval Medical Technologies
8.5.1. Company Overview
8.5.2. Technology Overview
8.5.3. Product Portfolio
8.5.4. Recent Developments
 
8.6. Xeris Pharmaceuticals
8.6.1. Company Overview
8.6.2. Technology Overview
8.6.3. Product Portfolio
8.6.3.1. G-Pen™ Autoinjector
8.6.3.2. DiazePen™ Autoinjector
8.6.4. Recent Developments
 
8.7. Zion Clinical Pharmacy
8.7.1. Company Overview
8.7.2. Product Portfolio
 
9. Global Autoinjectors Market Forecast, 2016 - 2026
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Overall Autoinjectors: Market Size and Forecast
9.3.1. Regional Market Size and Forecast: US, Europe, Asia Pacific and Rest of the World
9.3.2. Overall Disposable Autoinjectors: Market Size and Forecast
9.3.3. Overall Reusable Autoinjectors: Market Size and Forecast
9.3.4. Overall Subcutaneous Autoinjectors: Market Size and Forecast
9.3.5. Overall Intramuscular Autoinjectors: Market Size and Forecast
9.4. Autoinjectors for Anaphylaxis: Market Size and Forecast
9.4.1. Disposable Autoinjectors for Anaphylaxis: Market Size and Forecast
9.4.2. Reusable Autoinjectors for Anaphylaxis: Market Size and Forecast
9.4.3. Subcutaneous Autoinjectors for Anaphylaxis: Market Size and Forecast
9.4.4. Intramuscular Autoinjectors for Anaphylaxis: Market Size and Forecast
9.5. Autoinjectors for Multiple Sclerosis: Market Size and Forecast
9.5.1. Disposable Autoinjectors for Multiple Sclerosis: Market Size and Forecast
9.5.2. Reusable Autoinjectors for Multiple Sclerosis: Market Size and Forecast
9.5.3. Subcutaneous Autoinjectors for Multiple Sclerosis: Market Size and Forecast
9.5.4. Intramuscular Autoinjectors for Multiple Sclerosis: Market Size and Forecast
9.6. Autoinjectors for Rheumatoid Arthritis: Market Size and Forecast
9.6.1. Disposable Autoinjectors for Rheumatoid Arthritis: Market Size and Forecast
9.6.2. Reusable Autoinjectors for Rheumatoid Arthritis: Market Size and Forecast
9.6.3. Subcutaneous Autoinjectors for Rheumatoid Arthritis: Market Size and Forecast
9.6.4. Intramuscular Autoinjectors for Rheumatoid Arthritis: Market Size and Forecast
9.7. Autoinjectors for Migraine: Market Size and Forecast
9.7.1. Disposable Autoinjectors for Migraine: Market Size and Forecast
9.7.2. Reusable Autoinjectors for Migraine: Market Size and Forecast
9.7.3. Subcutaneous Autoinjectors for Migraine: Market Size and Forecast
9.7.4. Intramuscular Autoinjectors for Migraine: Market Size and Forecast
9.8. Autoinjectors for Diabetes: Market Size and Forecast
9.8.1. Disposable Autoinjectors for Diabetes: Market Size and Forecast
9.8.2. Reusable Autoinjectors for Diabetes: Market Size and Forecast
9.8.3. Subcutaneous Autoinjectors for Diabetes: Market Size and Forecast
9.8.4. Intramuscular Autoinjectors for Diabetes: Market Size and Forecast
9.9. Autoinjectors for Other Diseases: Market Size and Forecast
9.9.1. Disposable Autoinjectors for Other Diseases: Market Size and Forecast
9.9.2. Reusable Autoinjectors for Other Diseases: Market Size and Forecast
9.9.3. Subcutaneous Autoinjectors for Other Diseases: Market Size and Forecast
9.9.4. Intramuscular Autoinjectors for Other Diseases: Market Size and Forecast
 
10. Future Growth Opportunities
10.1. Chapter Overview
10.2. Life Cycle Management
10.3. Growing Pipeline of Biologics and Biosimilars
10.4. Emerging Target Indications for Autoinjectors
10.5. Expansion/ Adoption in the Emerging Regions
10.6. Specific Pockets of Growth
 
11. Interview Transcripts
11.1. Chapter Overview
11.2. Douglas Marenzi, Managing Director, PHC Injection Device Technologies
11.3. Tsachi Shaked, Senior Marketing and BD Director, Injectable Drug Delivery Devices, Elcam Medical
 
12. Conclusion
12.1. A Rapidly Growing Market Improving Patient Satisfaction
12.2. Growing Pipeline of Biologics and Life Cycle Management are Amongst the Key Drivers of the Industry
12.3. Several Combination Products Have Been Approved and Many are under Development
12.4. Anaphylaxis Has Dominated the Market So Far; Multiple Sclerosis, Rheumatoid Arthritis, Migraine, Psoriasis and Diabetes Have Witnessed Rising Adoption
12.5. Continued Growth in Disposable Devices; Increase in Demand for Reusable Devices
12.6. Established Firms Leading the Market; New Entrants are Fostering Continued Innovation
12.7. Next Generation Autoinjectors are on Their Way
12.8. Despite Being Over Two Decades Old, Market is still Evolving with Significant Growth Expected in the Coming Decade
12.9. Concluding Remarks
 
13. Appendix 1: Tabulated Data
 
14. Appendix 2: List of Companies and Organizations

List of Figures

Figure 2.1  Market Evolution: 2016, 2021, 2026 (USD Million)
Figure 3.1  Types of Drug Delivery Systems
Figure 3.2  Types of Self-Injection Devices
Figure 3.3  Cartridge Based Autoinjectors v/s Prefilled Syringe Based Autoinjectors
Figure 3.4  Autoinjector: Components
Figure 3.5  Autoinjector: Classification
Figure 4.1  Dual Chamber Cartridge
Figure 4.2  Glass Prefilled Syringes: Advantages and Disadvantages
Figure 4.3  Plastic Prefilled Syringes: Advantages and Disadvantages
Figure 5.1  Autoinjectors: Distribution by Players
Figure 5.2  Autoinjectors: Distribution by Type of Primary Drug Container
Figure 5.3  Autoinjectors: Distribution by Usability
Figure 5.4  Autoinjectors: Distribution by Type of Dosage
Figure 5.5  Autoinjectors: Distribution by Route of Administration
Figure 5.6  Approved Combination Products: Distribution by Players
Figure 5.7  Approved Combination Products: Distribution by Indication
Figure 5.8  Approved Combination Products: Distribution by Type of Primary Drug Container
Figure 5.9  Approved Combination Products: Distribution by Usability
Figure 5.10  Approved Combination Products: Distribution by Route of Administration
Figure 5.11  Approved Combination Products: Distribution by Target Drug
Figure 5.12  Autoinjectors (Disposable): Product Competitiveness Analysis
Figure 5.13  Autoinjectors (Reusable): Product Competitiveness Analysis
Figure 6.1  Adrenaline / Epinephrine: History of Development
Figure 6.2  Adrenaline / Epinephrine: Historical Sales (USD Million), 2012 - 2014
Figure 6.3  Interferon beta-1a/Interferon beta-1b: History of Development
Figure 6.4  Interferon beta-1a: Historical Sales (USD Million), 2012 - 2014
Figure 6.5  Interferon beta-1b: Historical Sales (USD Million), 2012 - 2014
Figure 7.1  Bespak Sales (GBP Million), FY 2010-H1 2016 
Figure 7.2  Bespak Injectables: Autoinjectors
Figure 7.3  Bespak Injectables: Syrina™ Autoinjectors
Figure 7.4  Delfu Autoinjectors: Components
Figure 7.5  Applications of Delfu Autoinjectors
Figure 7.6  DALI Medical Devices: Autoinjectors
Figure 7.7  SAN-L: Step Operations
Figure 7.8  SAN-P: Step Operations
Figure 7.9  SAN-DV: Step Operations
Figure 7.10  SAN-DV Pro: Step Operations
Figure 7.11  Elcam Medical: Products 
Figure 7.12  Elcam Medical: Flexi-Q Autoinjectors
Figure 7.13  Flexi-Q PFS: Components
Figure 7.14  Flexi-Q PFS: Step Operations
Figure 7.15  Flexi-Q DV: Components
Figure 7.16  Flexi-Q DV: Step Operations
Figure 7.17  Flexi-Q mMU: Components
Figure 7.18  Flexi-Q eMU: Components
Figure 7.19  Flexi-Q mMU / Flexi-Q eMU: Step Operations
Figure 7.20  Meridian Medical Technologies: Autoinjectors
Figure 7.21  ATNAA: Step Operations
Figure 7.22  Diazepam Autoinjector C-IV: Step Operations
Figure 7.23  DuoDote® Autoinjector: Step Operations
Figure 7.24  Morphine Autoinjector: Step Operations
Figure 7.25  Pralidoxime Chloride Autoinjector: Step Operations
Figure 7.26  EpiPen®: Step Operations
Figure 7.27  ALSUMA® Autoinjector: Step Operations
Figure 7.28  Vanquix™ Autoinjector: Step Operations
Figure 7.29  Owen Mumford: Cartridge-Based Injection Pens
Figure 7.30  Owen Mumford: Autoinjectors
Figure 7.31  Autoject® Micro: Step Operations
Figure 7.32  Autoject® 2 Autoinjector: Step Operations
Figure 7.33  Autoject® Mini: Step Operations
Figure 7.34  Autoject® Uni: Step Operations
Figure 7.35  Autoject® Multi: Step Operations
Figure 7.36  Autoject® Flex: Step Operations
Figure 7.37  SHL Medical: Product Portfolio
Figure 7.38  SHL Medical: Prefilled Syringe Based Autoinjectors
Figure 7.39  SHL Medical: Cartridge Based Autoinjectors
Figure 7.40  SHL Medical: Two-Step Autoinjectors
Figure 7.41  SHL Medical Two-Step Autoinjectors: Step Operations
Figure 7.42  SHL Medical: Three-Step Autoinjectors
Figure 7.43  DAI®: Step Operations
Figure 7.44  DAI®-R: Step Operations
Figure 7.45  SDI-MIX®+NIT™: Step Operations
Figure 7.46  Union Medico:  45˚ Autoinjector Portfolio
Figure 7.47  Union Medico: Parts of 45˚/R Autoinjector
Figure 7.48  Union Medico: Types of 45˚/R Autoinjector
Figure 7.49  Union Medico: Types of 90˚ Autoinjectors
Figure 7.50  SuperGrip™ Autoinjector: Components
Figure 7.51  Exclusive™: Components 
Figure 7.52  Ypsomed Sales (CHF Million), FY 2011- H1 2016 
Figure 7.53  Ypsomed: Sales by Business Divisions, FY 2015 (CHF Million, %)
Figure 7.54  Ypsomed: Sales by Business Divisions, H1 2016 (CHF Million, %)
Figure 7.55  Ypsomed: Cartridge Based Pen-injectors
Figure 7.56  Ypsomed: Cartridge Based Dual Chamber Pen-injectors
Figure 7.57  Ypsomed: Prefilled Syringe or Cartridge Based Autoinjectors
Figure 7.58  YpsoMate®: Step Operations
Figure 7.59  VarioJect™: Step Operations
Figure 7.60  YpsoMate® Smart:  Step Operations
Figure 8.1  XeriSol™ Technology: Working Mechanism
Figure 8.2  Trimix Autoinjector: Components
Figure 9.1  Overall Autoinjectors Market (Number of Units, Millions), 2016 - 2026
Figure 9.2  Overall Autoinjectors Market (USD Million), 2016 - 2026
Figure 9.3  Regional Autoinjectors Market (Number of Units, Millions), 2016 - 2026
Figure 9.4  Regional Autoinjectors Market (USD Million), 2016 - 2026
Figure 9.5  Overall Disposable Autoinjectors Market (Number of Units, Million), 2016 - 2026
Figure 9.6  Overall Disposable Autoinjectors Market (USD Million), 2016 - 2026
Figure 9.7  Overall Reusable Autoinjectors Market (Number of Units, Million), 2016 - 2026
Figure 9.8  Overall Reusable Autoinjectors Market (USD Million), 2016 - 2026
Figure 9.9  Overall Subcutaneous Autoinjectors Market (Number of Units, Million), 2016 - 2026
Figure 9.10  Overall Subcutaneous Autoinjectors Market (USD Million), 2016 - 2026
Figure 9.11  Overall Intramuscular Autoinjectors Market (Number of Units, Million), 2016 - 2026
Figure 9.12 Overall Intramuscular Autoinjectors Market (USD Million), 2016 - 2026
Figure 9.13  Autoinjectors for Anaphylaxis Market (Number of Units, Millions), 2016 - 2026
Figure 9.14  Autoinjectors for Anaphylaxis Market (USD Million), 2016 - 2026
Figure 9.15  Disposable Autoinjectors for Anaphylaxis (Number of Units, Million), 2016 - 2026
Figure 9.16  Disposable Autoinjectors for Anaphylaxis (USD Million), 2016 - 2026
Figure 9.17  Reusable Autoinjectors for Anaphylaxis (Number of Units, Million), 2016 - 2026
Figure 9.18  Reusable Autoinjectors for Anaphylaxis (USD Million), 2016 - 2026
Figure 9.19  Subcutaneous Autoinjectors for Anaphylaxis (Number of Units, Million), 2016 - 2026
Figure 9.20  Subcutaneous Autoinjectors for Anaphylaxis (USD Million), 2016 - 2026
Figure 9.21  Intramuscular Autoinjectors for Anaphylaxis (Number of Units, Million), 2016 - 2026
Figure 9.22  Intramuscular Autoinjectors for Anaphylaxis (USD Million), 2016 - 2026
Figure 9.23  Autoinjectors for Multiple Sclerosis Market (Number of Units, Million), 2016 - 2026
Figure 9.24  Autoinjectors for Multiple Sclerosis Market (USD Million), 2016 - 2026
Figure 9.25  Disposable Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016 - 2026
Figure 9.26  Disposable Autoinjectors for Multiple Sclerosis (USD Million), 2016 - 2026 
Figure 9.27  Reusable Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016 - 2026
Figure 9.28  Reusable Autoinjectors for Multiple Sclerosis (USD Million), 2016 - 2026
Figure 9.29  Subcutaneous Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016 - 2026
Figure 9.30  Subcutaneous Autoinjectors for Multiple Sclerosis (USD Million), 2016 - 2026
Figure 9.31  Intramuscular Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016 - 2026
Figure 9.32  Intramuscular Autoinjectors for Multiple Sclerosis (USD Million), 2016 - 2026
Figure 9.33  Autoinjectors for Rheumatoid Arthritis Market (Number of Units, Million), 2016 - 2026
Figure 9.34  Autoinjectors for Rheumatoid Arthritis Market (USD Million), 2016 - 2026
Figure 9.35  Disposable Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016 - 2026
Figure 9.36  Disposable Autoinjectors for Rheumatoid Arthritis (USD Million), 2016 - 2026
Figure 9.37  Reusable Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016 - 2026
Figure 9.38  Reusable Autoinjectors for Rheumatoid Arthritis (USD Million), 2016 - 2026
Figure 9.39  Subcutaneous Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016 - 2026
Figure 9.40  Subcutaneous Autoinjectors for Rheumatoid Arthritis (USD Million), 2016 - 2026
Figure 9.41  Intramuscular Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016 - 2026
Figure 9.42  Intramuscular Autoinjectors for Rheumatoid Arthritis (USD Million), 2016 - 2026
Figure 9.43  Autoinjectors for Migraine Market (Number of Units, Million), 2016 - 2026
Figure 9.44  Autoinjectors for Migraine Market (USD Million), 2016 - 2026
Figure 9.45  Disposable Autoinjectors for Migraine (Number of Units, Million), 2016 - 2026
Figure 9.46  Disposable Autoinjectors for Migraine (USD Million), 2016 - 2026
Figure 9.47  Reusable Autoinjectors for Migraine (Number of Units, Million), 2016 - 2026
Figure 9.48  Reusable Autoinjectors for Migraine (USD Million), 2016 - 2026
Figure 9.49  Subcutaneous Autoinjectors for Migraine (Number of Units, Million), 2016 - 2026
Figure 9.50 Subcutaneous Autoinjectors for Migraine (USD Million), 2016 - 2026
Figure 9.51  Intramuscular Autoinjectors for Migraine (Number of Units, Million), 2016 - 2026
Figure 9.52  Intramuscular Autoinjectors for Migraine (USD Million), 2016 - 2026
Figure 9.53  Autoinjectors for Diabetes Market (Number of Units, Million), 2016 - 2026
Figure 9.54  Autoinjectors for Diabetes Market (USD Million), 2016 - 2026
Figure 9.55  Disposable Autoinjectors for Diabetes (Number of Units, Million), 2016 - 2026
Figure 9.56  Disposable Autoinjectors for Diabetes (USD Million), 2016 - 2026
Figure 9.57  Reusable Autoinjectors for Diabetes (Number of Units, Million), 2016 - 2026
Figure 9.58  Reusable Autoinjectors for Diabetes (USD Million), 2016 - 2026
Figure 9.59  Subcutaneous Autoinjectors for Diabetes (Number of Units, Million), 2016 - 2026
Figure 9.60  Subcutaneous Autoinjectors for Diabetes (USD Million), 2016 - 2026
Figure 9.61  Intramuscular Autoinjectors for Diabetes (Number of Units, Million), 2016 - 2026
Figure 9.62  Intramuscular Autoinjectors for Diabetes (USD Million), 2016 - 2026
Figure 9.63  Autoinjectors for Other Diseases Market (Number of Units, Million), 2016 - 2026
Figure 9.64  Autoinjectors for Other Diseases Market (USD Million), 2016 - 2026
Figure 9.65  Disposable Autoinjectors for Other Diseases (Number of Units, Million), 2016 - 2026
Figure 9.66  Disposable Autoinjectors for Other Diseases (USD Million), 2016 - 2026
Figure 9.67  Reusable Autoinjectors for Other Diseases (Number of Units, Million), 2016 - 2026
Figure 9.68  Reusable Autoinjectors for Other Diseases (USD Million), 2016 - 2026
Figure 9.69  Subcutaneous Autoinjectors for Other Diseases (Number of Units, Million), 2016 - 2026
Figure 9.70  Subcutaneous Autoinjectors for Other Diseases (USD Million), 2016 - 2026
Figure 9.71  Intramuscular Autoinjectors for Other Diseases (Number of Units, Million), 2016 - 2026
Figure 9.72  Intramuscular Autoinjectors for Other Diseases (USD Million), 2016 - 2026
Figure 10.1  Autoinjectors: Future Growth Opportunities
Figure 10.2  Numbers of Biologics Approved by the FDA, 2009-2015
Figure 12.1  Autoinjectors Market (2016, 2026): Distribution by Therapeutic Area (USD Million, #Millions)
Figure 12.2  Autoinjectors Market (2016, 2026): Distribution by Usability (USD Million, #Millions)
Figure 12.3  Autoinjectors Market (2016, 2026): Distribution by Route of Administration (USD Million, #Millions)

List of Tables

Table 3.1  Benefits of Autoinjectors 
Table 4.1  Advantages of Glass as Barrel 
Table 4.2  Companies Developing Cartridges
Table 4.3  Classification of Prefilled Syringes 
Table 4.4  Glass Prefilled Syringes Available in the Market, 2015
Table 4.5  Plastic Prefilled Syringes Available in the Market, 2015
Table 5.1  List of Autoinjector Devices 
Table 5.2  Autoinjectors: Distribution by Type of Dosage
Table 5.3  List of Approved Combination Products
Table 5.4  List of Pipeline Combination Products
Table 6.1  Drugs Available / Being Evaluated With Autoinjectors
Table 6.2  Adrenaline / Epinephrine: Commercially Available Autoinjectors
Table 6.3  Adrenaline /Epinephrine: Other Formulations
Table 6.4  Interferon beta-1a: Autoinjectors
Table 6.5  Interferon beta-1b: Autoinjectors 
Table 6.6  Interferon-beta Drugs: Other Dosage Forms
Table 6.7  Marketed Molecules: Most Likely Candidates for Autoinjectors
Table 6.8  Marketed Molecules: Likely Candidates for Autoinjectors
Table 6.9  Marketed Molecules: Less Likely Candidates for Autoinjectors
Table 6.10 Pipeline Molecules: Most Likely Candidates for Autoinjectors
Table 6.11  Pipeline Molecules: Likely Candidates for Autoinjectors 
Table 6.12  Pipeline Molecules: Less Likely Candidates for Autoinjectors
Table 7.1  Changzhou Delfu: Autoinjectors
Table 7.2  Delfu Autoinjectors: Specifications
Table 7.3  Elcam Medical: Comparison of Autoinjectors 
Table 7.4  ATNAA: Constituents of Atropine Diluent (0.7mL)
Table 7.5  ATNAA: Constituents of Pralidoxime Chloride Diluent (2mL)
Table 7.6  AtroPen®: Comparison of AtroPen® Autoinjectors (Based on Dose Strengths)
Table 7.7  Diazepam Autoinjector C-IV: Constituents of Diazepam Diluent (1 mL)
Table 7.8  DuoDote® Autoinjector: Constituents of Atropine Diluent (0.7mL)
Table 7.9  DuoDote® Autoinjector: Constituents of Pralidoxime Chloride Diluent (2mL) 
Table 7.10  Morphine Autoinjector C-II: Constituents of Diluent 
Table 7.11  Pralidoxime Chloride Autoinjector: Constituents of Diluent (2mL)
Table 7.12  Meridian Medical Technologies: Comparison of Autoinjectors
Table 7.13  Owen Mumford: Comparison of AutoJect® 2 Variants
Table 7.14  Owen Mumford:  Comparison of Autoject® 2 Variants Based on Size of the Needle    
Table 7.15  Owen Mumford: Comparison of Autoject® Mini Variants Based on Size
Table 7.16  Owen Mumford: Autoject® Flex Variants (Features)
Table 7.17  Owen Mumford: Comparison of Autoinjectors
Table 7.18 SHL: Comparison of Two-Step Disposable Autoinjectors
Table 7.19  SHL: Comparison of Three-Step Disposable Autoinjectors
Table 7.20  Union Medico: Comparison of 45˚ Autoinjectors
Table 7.21  Union Medico: Comparison of 90˚ Autoinjectors
Table 7.22  Ypsomed: Comparison of Autoinjectors
Table 10.1  Emerging Indications for Autoinjectors
Table 13.1  Autoinjectors: Distribution by Players
Table 13.2 Autoinjectors: Distribution by Type of Primary Drug Container
Table 13.3 Autoinjectors: Distribution by Usability
Table 13.4 Autoinjectors: Distribution by Type of Dosage
Table 13.5 Autoinjectors: Distribution by Route of Administration 
Table 13.6 Approved Combination Products: Distribution by Players
Table 13.7 Approved Combination Products: Distribution by Indication
Table 13.8 Approved Combination Products: Distribution by Type of Primary Drug Container
Table 13.9 Approved Combination Products: Distribution by Usability
Table 13.10 Approved Combination Products: Distribution by Route of Administration 
Table 13.11 Autoinjectors: Distribution by Target Drug
Table 13.12 Adrenaline / Epinephrine: Historical Sales (USD Million), 2012 - 2014 
Table 13.13 Interferon beta-1a: Historical Sales (USD Million), 2012 - 2014 
Table 13.14 Interferon beta-1a: Historical Sales (USD Million), 2012 - 2014 
Table 13.15 Bespak Sales (GBP Million), FY 2010-H1 2016 
Table 13.16 Ypsomed Sales (CHF Million), FY 2011- H1 2016 
Table 13.17 Ypsomed: Sales by Business Divisions (CHF Million, %), FY 2015 
Table 13.18 Ypsomed: Sales by Business Divisions (CHF Million, %), H1 2016 
Table 13.19 Overall Autoinjectors Market (Number of Units, Millions), 2016 – 2026
Table 13.20 Overall Autoinjectors Market (USD Million), 2016 – 2026
Table 13.21 Regional Autoinjectors Market (Number of Units, Millions), 2016 - 2026 
Table 13.22 Regional Autoinjectors Market (USD Million), 2016 – 2026
Table 13.23 Overall Disposable Autoinjectors Market (Number of Units, Million), 2016 – 2026
Table 13.24 Overall Disposable Autoinjectors Market (USD Million), 2016 - 2026 
Table 13.25 Overall Reusable Autoinjectors Market (Number of Units, Million), 2016 - 2026 
Table 13.26 Overall Reusable Autoinjectors Market (USD Million), 2016 - 2026 
Table 13.27 Overall Subcutaneous Autoinjectors Market (Number of Units, Million), 2016 - 2026 
Table 13.28 Overall Subcutaneous Autoinjectors Market (USD Million), 2016 – 2026
Table 13.29 Overall Intramuscular Autoinjectors Market (Number of Units, Million), 2016 - 2026 
Table 13.30 Overall Intramuscular Autoinjectors Market (USD Million), 2016 - 2026 
Table 13.31 Autoinjectors for Anaphylaxis Market (Number of Units, Millions), 2016 - 2026 
Table 13.32 Autoinjectors for Anaphylaxis Market (USD Million), 2016 - 2026 
Table 13.33 Disposable Autoinjectors for Anaphylaxis (Number of Units, Million), 2016 - 2026 
Table 13.34 Disposable Autoinjectors for Anaphylaxis (USD Million), 2016 - 2026 
Table 13.35 Reusable Autoinjectors for Anaphylaxis (Number of Units, Million), 2016 - 2026 
Table 13.36 Reusable Autoinjectors for Anaphylaxis (USD Million), 2016 - 2026 
Table 13.37 Subcutaneous Autoinjectors for Anaphylaxis (Number of Units, Million), 2016 - 2026 
Table 13.38 Subcutaneous Autoinjectors for Anaphylaxis (USD Million), 2016 - 2026 
Table 13.39 Intramuscular Autoinjectors for Anaphylaxis (Number of Units, Million), 2016 - 2026 
Table 13.40 Intramuscular Autoinjectors for Anaphylaxis (USD Million), 2016 - 2026 
Table 13.41 Autoinjectors for Multiple Sclerosis Market (Number of Units, Million), 2016 - 2026 
Table 13.42 Autoinjectors for Multiple Sclerosis Market (USD Million), 2016 - 2026 
Table 13.43 Disposable Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016 - 2026 
Table 13.44 Disposable Autoinjectors for Multiple Sclerosis (USD, Million), 2016 - 2026 
Table 13.45 Reusable Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016 – 2026
Table 13.46 Reusable Autoinjectors for Multiple Sclerosis (USD Million), 2016 - 2026 
Table 13.47 Subcutaneous Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016 -2026
Table 13.48 Subcutaneous Autoinjectors for Multiple Sclerosis (USD Million), 2016 - 2026 
Table 13.49 Intramuscular Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016 – 2026
Table 13.50     Intramuscular Autoinjectors for Multiple Sclerosis (USD Million), 2016 - 2026 
Table 13.51 Autoinjectors for Rheumatoid Arthritis Market (Number of Units, Million), 2016 - 2026 
Table 13.52 Autoinjectors for Rheumatoid Arthritis Market (USD Million), 2016 - 2026 
Table 13.53 Disposable Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016 - 2026 
Table 13.54 Disposable Autoinjectors for Rheumatoid Arthritis (USD Million), 2016 - 2026 
Table 13.55 Reusable Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016 - 2026 
Table 13.56 Reusable Autoinjectors for Rheumatoid Arthritis (USD Million), 2016 - 2026 
Table 13.57 Subcutaneous Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016 - 2026 
Table 13.58 Subcutaneous Autoinjectors for Rheumatoid Arthritis (USD Million), 2016 - 2026 
Table 13.59 Intramuscular Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016 - 2026 
Table 13.60 Intramuscular Autoinjectors for Rheumatoid Arthritis (USD Million), 2016 - 2026 
Table 13.61 Autoinjectors for Migraine Market (Number of Units, Million), 2016 - 2026 
Table 13.62 Autoinjectors for Migraine Market (USD Million), 2016 - 2026 
Table 13.63 Disposable Autoinjectors for Migraine (Number of Units, Million), 2016 - 2026 
Table 13.64 Disposable Autoinjectors for Migraine (USD Million), 2016 - 2026 
Table 13.65 Reusable Autoinjectors for Migraine (Number of Units, Million), 2016 - 2026 
Table 13.66 Reusable Autoinjectors for Migraine (USD Million), 2016 - 2026 
Table 13.67 Subcutaneous Autoinjectors for Migraine (Number of Units, Million), 2016 - 2026 
Table 13.68 Subcutaneous Autoinjectors for Migraine (USD Million), 2016 - 2026 
Table 13.69 Intramuscular Autoinjectors for Migraine (Number of Units, Million), 2016 - 2026 
Table 13.70 Intramuscular Autoinjectors for Migraine (USD Million), 2016 - 2026 
Table 13.71 Autoinjectors for Diabetes Market (Number of Units, Million), 2016 - 2026 
Table 13.72 Autoinjectors for Diabetes Market (USD Million), 2016 - 2026 
Table 13.73 Disposable Autoinjectors for Diabetes (Number of Units, Million), 2016 - 2026 
Table 13.74 Disposable Autoinjectors for Diabetes (USD Million), 2016 - 2026 
Table 13.75 Reusable Autoinjectors for Diabetes (Number of Units, Million), 2016 - 2026 
Table 13.76 Reusable Autoinjectors for Diabetes (USD Million), 2016 - 2026 
Table 13.77 Subcutaneous Autoinjectors for Diabetes (Number of Units, Million), 2016 - 2026 
Table 13.78 Subcutaneous Autoinjectors for Diabetes (USD Million), 2016 - 2026 
Table 13.79 Intramuscular Autoinjectors for Diabetes (Number of Units, Million), 2016 - 2026 
Table 13.80 Intramuscular Autoinjectors for Diabetes (USD Million), 2016 - 2026 
Table 13.81 Autoinjectors for Other Diseases Market (Number of Units, Million), 2016 - 2026 
Table 13.82 Autoinjectors for Other Diseases Market (USD Million), 2016 - 2026 
Table 13.83 Disposable Autoinjectors for Other Diseases (Number of Units, Million), 2016 – 2026
Table 13.84 Disposable Autoinjectors for Other Diseases (USD Million), 2016 - 2026 
Table 13.85 Reusable Autoinjectors for Other Diseases (Number of Units, Million), 2016 – 2026
Table 13.86 Reusable Autoinjectors for Other Diseases (USD Million), 2016 - 2026 
Table 13.87 Subcutaneous Autoinjectors for Other Diseases (Number of Units, Million), 2016 - 2026 
Table 13.88 Subcutaneous Autoinjectors for Other Diseases (USD Million), 2016 - 2026 
Table 13.89 Intramuscular Autoinjectors for Other Diseases (Number of Units, Million), 2016 - 2026 
Table 13.90 Intramuscular Autoinjectors for Other Diseases (USD Million), 2016 – 2026
Table 13.91 Numbers of Biologics Approved by the USFDA, 2009-2015
Table 13.92 Autoinjectors Market (2016, 2026): Distribution by Therapeutic Area  (USD Million) 
Table 13.93 Autoinjectors Market (2016, 2026): Distribution by Therapeutic Area (Number of Units) 
Table 13.94 Autoinjectors Market (2016, 2026): Distribution by Usability (USD Million) 
Table 13.95 Autoinjectors Market (2016, 2026): Distribution by Usability (Number of Units)
Table 13.96 Autoinjectors Market (2016, 2026): Distribution by Route of Administration (USD Million) 
Table 13.97 Autoinjectors Market (2016, 2026): Distribution by Route of Administration (Number of Units) 

Listed Companies

The following companies and organizations have been mentioned in the report.

  1. 3P Limited
  2. AbbVie
  3. Ablynx
  4. Aguettant
  5. ALK-Abelló A/S
  6. Allergy Therapeutics
  7. Alliance Healthcare
  8. Allozyne (Acquired by MedImmune)
  9. Amag Pharmaceuticals
  10. Amedra Pharmaceuticals (Acquired by Impax Laboratories)
  11. Amgen
  12. Antares Phama
  13. Aptar Pharma
  14. Arte Corporation
  15. Aventis Pharma
  16. Bang & Olufsen Medicom
  17. Bayer Healthcare
  18. Becton Dickinson & Co
  19. Bespak
  20. Biogen Idec
  21. Bioprojet
  22. Boehringer Ingelheim
  23. Bristol-Myers Squibb
  24. Brunswick Biomedical Corporation
  25. Cambridge Capital Group
  26. Cambridge Consultants
  27. Celgene Corporation
  28. Central Texas Angel Network
  29. Changzhou Delfu Technology
  30. ChemProtect SK
  31. Chugai Pharmaceutical Co. Ltd
  32. CiToxLab
  33. Consort Medical
  34. Cytheris
  35. CytoDyn
  36. Daikyo Seiko
  37. DALI Medical Devices
  38. Disetronic
  39. Dr. Reddy's Laboratories
  40. Elcam Medical
  41. Eli Lilly
  42. EMD Serono
  43. Emergent Biosolutions
  44. Exsulin
  45. FFT Medical
  46. Future Injection Technologies
  47. Gerresheimer
  48. GlaxoSmithKline
  49. Global Pharma
  50. Globe Medical Tech
  51. Haselmeier AG
  52. Hemispherx Bioscience
  53. Hoffmann-La Roche
  54. Hospira
  55. Immune Response Biopharma
  56. Immunex
  57. Injectech
  58. Ionis Pharmaceuticals
  59. Janssen Biotech
  60. JHP Pharmaceuticals
  61. Jiangsu Delfu medical device
  62. Johnson & Johnson
  63. Kaleo (formerly known as Intelliject)
  64. King Pharmaceuticals
  65. Kisling AG
  66. Labrys Biologics  (Acquired by Teva)
  67. Lincoln Medical (Acquired by Bioprojet Pharma)
  68. Lineage Therapeutics
  69. LyoGo
  70. medac GmbH
  71. Medac Pharma
  72. Medeca Pharma
  73. Medical Valley Alliance
  74. MedPro
  75. Merck
  76. Merck Serono
  77. Meridian Medical Technologies
  78. Merz Pharmaceuticals
  79. MSD Animal Health
  80. Mylan
  81. National Health Service
  82. Nemera
  83. Nipro Corporation (Acquired MGlas)
  84. Novartis
  85. Novo Nordisk
  86. Nuance Design
  87. Nuova Ompi
  88. Nuron Biotech
  89. Otsuka Pharmaceuticals
  90. Oval Medical Technologies
  91. Owen Mumford
  92. PA Consulting Group
  93. Palatin Technologies
  94. PDL BioPharma
  95. Pfizer
  96. Pharma-Pen
  97. PhaseBio Pharmaceuticals
  98. PHC Injection Device Technologies
  99. Plas-Tech Engineering
  100. Project Pharmaceutics
  101. Redmile Group
  102. Regeneron Pharmaceuticals
  103. Revolutions Medical
  104. Roselabs Bioscience
  105. Sabby Management
  106. Sanofi
  107. Sanofi Pasteur
  108. Santarus
  109. Scandinavian Health Limited Group
  110. School of Medicine at the University of Texas Health Science Center San Antonio
  111. SCHOTT AG
  112. Schreiner MediPharm
  113. Sciele Pharma (Now Known as Shionogi Pharma)
  114. Shandong Weigao Group
  115. SiliCycle
  116. SiO2 Medical Products
  117. SKINSORB
  118. Sumitomo Dainippon Pharma
  119. Sun Pharma
  120. Survival Technologies
  121. Taisei Kako
  122. Takeda
  123. Team Consulting
  124. Terumo Corporation
  125. Teva Pharma Industries
  126. Texas Diabetes Institute (TDI) of the University Health System
  127. The Cambridge Angels
  128. The McNair Group
  129. The Medical House (TMH)
  130. Tonghua Dongbao Pharmaceutical
  131. UCB
  132. Uman Pharma
  133. Unilife Corporation
  134. Union Medico
  135. US Medical Instruments
  136. US WorldMeds
  137. Valeant Pharmaceutical International
  138. Vetter Pharma
  139. West Pharmaceutical Services
  140. Windgap Medical
  141. Xeris Pharmaceuticals
  142. Ypsomed Delivery Systems
  143. Zion Clinical Pharmacy
     

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 2,349

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com